Strategy

1. (erythropoietin* or EPO).tw.
2. Erythropoietin/
3. Receptors, erythropoietin/
4. erythropoiesis.tw.
5. Erythropoiesis/
6. (epoetin adj1 (alfa or beta or theta or zeta)).tw.
7. darbepoetin.tw.
8. CERA.tw.
9. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp).tw.
10. or/1-9
11. an?emi?.tw.
12. exp anemia/
13. 11 or 12
14. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or lymphoma* or oncolog* or chemotherap*).tw.
15. exp neoplasms/
16. 14 or 15
17. (random* or rct* or “controlled trial*” or “clinical trial*”).tw.
18. randomized controlled trial.pt.
19. 17 or 18
20. 10 and 13 and 16 and 19
21. limit 20 to (english language and yr=”2004 -Current”)

Strategy

1. (erythropoietin* or EPO).tw.
2. erythropoiesis.tw.
3. (epoetin adj1 (alfa or beta or theta or zeta)).tw.
4. darbepoetin.tw.
5. CERA.tw.
6. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp).tw.
7. or/1-6
8. an?emi?.tw.
9. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or lymphoma* or oncolog* or chemotherap*).tw.
10. (random* or rct* or “controlled trial*” or “clinical trial*”).tw.
11. 7 and 8 and 9 and 10
12. limit 11 to yr=”2004 -Current”

Strategy

1. (erythropoietin* or EPO).tw.
2. Erythropoietin/
3. Receptors, erythropoietin/
4. recombinant erythropoietin/
5. erythropoiesis.tw.
6. Erythropoiesis/
7. (epoetin adj1 (alfa or beta or theta or zeta)).tw.
8. darbepoetin.tw.
9. novel erythropoiesis stimulating protein/
10. CERA.tw.
11. continuous erythropoiesis receptor activator/
12. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp).tw.
13. or/1-12
14. an?emi?.tw.
15. exp anemia/
16. 14 or 15
17. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or lymphoma* or oncolog* or chemotherap*).tw.
18. exp neoplasms/
19. 17 or 18
20. (random* or rct* or “controlled trial*” or “clinical trial*”).tw.
21. 13 and 16 and 19 and 20
22. limit 21 to (english language and yr=”2004 -Current”)

Strategy

1. (erythropoietin* or EPO):ti or (erythropoietin* or EPO):ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
2. MeSH descriptor: [Erythropoietin] explode all trees
3. MeSH descriptor: [Receptors, Erythropoietin] explode all trees
4. erythropoiesis:ti or erythropoiesis:ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
5. MeSH descriptor: [Erythropoiesis] explode all trees
6. (epoetin near/1 (alfa or beta or theta or zeta)):ti or (epoetin near/1 (alfa or beta or theta or zeta)):ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
7. darbepoetin:ti or darbepoetin:ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
8. CERA:ti or CERA:ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
9. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp):ti or (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp):ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
10. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
11. anemi? or anaemi?:ti or anemi? or anaemi?:ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
12. MeSH descriptor: [Anemia] explode all trees
13. #11 or #12
14. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumour* or tumor* or myelo* or lymphoma* or oncolog* or chemotherap*):ti or (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumour* or tumor* or myelo* or lymphoma* or oncolog* or chemotherap*):ab from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations
15. MeSH descriptor: [Neoplasms] explode all trees
16. #14 or #15
17. #10 and #13 and #16 from 2004, in Cochrane Reviews (Reviews and Protocols), Other Reviews, Trials, Technology Assessments and Economic Evaluations

Strategy

1. Title=((erythropoietin* or EPO)) OR Topic=((erythropoietin* or EPO))
2. Title=(erythropoiesis) OR Topic=(erythropoiesis)
3. Title=((epoetin near/0 (alfa or beta or theta or zeta))) OR Topic=((epoetin near/0 (alfa or beta or theta or zeta)))
4. Title=(darbepoetin) OR Topic=(darbepoetin)
5. Title=(CERA) OR Topic=(CERA)
6. Title=((eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp)) OR Topic=((eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp))
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6
8. Title=(anemi* OR anaemi*) OR Topic=(anemi* OR anaemi*)
9. TI=((cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumour* or tumor* or myelo* or lymphoma* or oncolog* or chemotherap*)) OR TS=((cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumour* or tumor* or myelo* or lymphoma* or oncolog* or chemotherap*))
10. Title=((random* or rct* or “controlled trial*” or “clinical trial*”)) OR Topic=((random* or rct* or “controlled trial*” or “clinical trial*”))
11. #7 AND #8 AND #9 AND #10 Timespan=2004-2013

Strategy

1. TI(erythropoietin* or EPO) OR AB(erythropoietin* or EPO)
2. (MH “Erythropoietin”)
3. TI(erythropoiesis) OR AB(erythropoiesis)
4. (MH “Erythropoiesis”)
5. TI(epoetin n0 (alfa or beta or theta or zeta)) OR AB(epoetin n0 (alfa or beta or theta or zeta))
6. TI(darbepoetin) OR AB(darbepoetin)
7. TI(CERA) OR AB(CERA)
8. TI(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp) OR AB(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp)
9. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
10. TI(anemi* or anaemi*) OR AB(anemi* or anaemi*)
11. (MH “Anemia+”)
12. S10 OR S11
13. TI(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or tumour* or myelo* or lymphoma* or oncolog* or chemotherap*) OR AB(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or tumour* or myelo* or lymphoma* or oncolog* or chemotherap*)
14. (MH “Neoplasms+”)
15. S13 OR S14
16. TI(random* or rct* or “controlled trial*” or “clinical trial*”) OR AB(random* or rct* or “controlled trial*” or “clinical trial*”)
17. PT(randomized controlled trial)
18. S16 OR S17
19. S9 AND S12 AND S15 AND S18

Date limited 2004–current.

Strategy

Lines 1–16: see MEDLINE clinical effectiveness strategy.

1. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”).tw.
2. (fiscal or funding or financial or finance* or expenditure* or budget*).tw.
3. (“resource* alloca*” or “resource* use”).tw.
4. exp Economics/
5. exp models, economic/
6. exp “Costs and Cost Analysis”/
7. Cost of illness/
8. ec.fs.
9. (decision adj2 (model* or tree* or analy*)).tw.
10. markov.tw.
11. decision trees/
12. or/17-27
13. 10 and 13 and 16 and 28
14. limit 29 to (english language and yr=”2004 -Current”)

Strategy

Lines 1–9: see MEDLINE In-Process & Other Non-Indexed Citations clinical effectiveness strategy.

1. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”).tw.
2. (fiscal or funding or financial or finance* or expenditure* or budget*).tw.
3. (“resource* alloca*” or “resource* use”).tw.
4. (decision adj2 (model* or tree* or analy*)).tw.
5. markov.tw.
6. or/10-14
7. 7 and 8 and 9 and 15
8. limit 16 to yr=”2004 -Current”

Strategy

Lines 1–19: see EMBASE clinical effectiveness strategy.

1. (pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”).tw.
2. (fiscal or funding or financial or finance* or expenditure* or budget*).tw.
3. (“resource* alloca*” or “resource* use”).tw.
4. exp Economics/
5. models, economic/
6. exp health economics/
7. exp “Costs and Cost Analysis”/
8. Cost of illness/
9. resource allocation/
10. pe.fs.
11. (decision adj2 (model* or tree* or analy*)).tw.
12. markov.tw.
13. decision trees/
14. or/20-32
15. 13 and 16 and 19 and 33
16. limit 34 to (english language and yr=”2004 -Current”)

Strategy

See CENTRAL clinical effectiveness strategy.

Strategy

Lines 1–9: see Web of Science clinical effectiveness strategy.

1. TI=((pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”)) OR TS=((pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”))
2. Title=((fiscal or funding or financial or finance* or expenditure* or budget*)) OR Topic=((fiscal or funding or financial or finance* or expenditure* or budget*))
3. Title=((“resource* alloca*” or “resource* use”)) OR Topic=((“resource* alloca*” or “resource* use”))
4. Title=((decision near/1 (model* or tree* or analy*))) OR Topic=((decision near/1 (model* or tree* or analy*)))
5. Title=(markov) OR Topic=(markov)
6. #14 OR #13 OR #12 OR #11 OR #10
7. #15 AND #9 AND #8 AND #7 Timespan=2004-2013

Strategy

Lines 1–15: see CINAHL clinical effectiveness strategy.

1. TI(pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”) OR AB(pharmacoeconomic* or economic* or price* or pricing* or cost* or cba or cea or cua or “health utilit*” or “value for money”)
2. TI(fiscal or funding or financial or finance* or expenditure* or budget*) OR AB(fiscal or funding or financial or finance* or expenditure* or budget*)
3. TI(“resource* alloca*” or “resource* use”) OR AB(“resource* alloca*” or “resource* use”)
4. (MH “Economics+”)
5. TI(decision n1 (model* or tree* or analy*)) OR AB(decision n1 (model* or tree* or analy*))
6. TI(markov) OR AB(markov)
7. (MH “Decision Trees”)
8. S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22
9. S9 AND S12 AND S15 AND S23

Date limited 2004–current.

Strategy

1. TI=(erythropoietin* or EPO)
2. TI=erythropoiesis
3. TI=(epoetin alfa or epoetin beta or epoetin theta or epoetin zeta)
4. TI=darbepoetin
5. TI=CERA
6. TI=(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp)
7. AB=(erythropoietin* or EPO)
8. AB=erythropoiesis
9. AB=(epoetin alfa or epoetin beta or epoetin theta or epoetin zeta)
10. AB=darbepoetin
11. AB=CERA
12. AB=(eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp)
13. CS=(1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12)
14. TI=(anaemi* or anemi*)
15. AB=(anaemi* or anemi*)
16. CS=(14 or 15)
17. TI=(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or tumour* or myelo* or lymphoma* or oncolog* or chemotherap*)
18. AB=(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumor* or tumour* or myelo* or lymphoma* or oncolog* or chemotherap*)
19. CS=(17 or 18)
20. CS=(13 and 16 and 19)

Strategy

Lines 1–16: see MEDLINE clinical effectiveness strategy.

1. (“quality of life” or QoL or HRQL or HRQoL).tw.
2. quality of life/
3. (“quality adjusted life year*” or QALY*).tw.
4. quality-adjusted life years/
5. “activities of daily living”.tw.
6. activities of daily living/
7. (“quality of wellbeing” or QWB or “QWB SA”).tw.
8. (“health* year* equivalent*” or HYE*).tw.
9. “health status”.tw.
10. health status/
11. health status indicators/
12. Psychometrics/
13. psychometric*.tw.
14. (“short form 36” or “SF-36” or SF36).tw.
15. (“short form 20” or “SF-20” or SF20).tw.
16. (“short form 12” or “SF-12” or SF12).tw.
17. (“short form 8” or “SF-8” or SF8).tw.
18. (Euroqol or “EQ-5D”).tw.
19. exp Questionnaires/
20. or/17-35
21. 10 and 13 and 16 and 36
22. limit 37 to (english language and yr=”2004 -Current”)

Strategy

Lines 1–9: see MEDLINE In-Process & Other Non-Indexed Citations clinical effectiveness strategy.

1. (“quality of life” or QoL or HRQL or HRQoL).tw.
2. (“quality adjusted life year*” or QALY*).tw.
3. “activities of daily living”.tw.
4. (“quality of wellbeing” or QWB or "QWB SA").tw.
5. (“health* year* equivalent*" or HYE*).tw.
6. “health status”.tw.
7. psychometric*.tw.
8. (“short form 36” or “SF-36” or SF36).tw.
9. (“short form 20” or “SF-20” or SF20).tw.
10. (“short form 12” or “SF-12” or SF12).tw.
11. (“short form 8” or “SF-8” or SF8).tw.
12. (Euroqol or “EQ-5D”).tw.
13. or/10-21
14. 7 and 8 and 9 and 22
15. limit 23 to yr=”2004 -Current”

Strategy

Lines 1–19: see EMBASE clinical effectiveness strategy.

1. (“quality of life” or QoL or HRQL or HRQoL).tw.
2. exp quality of life/
3. (“quality adjusted life year*” or QALY*).tw.
4. “activities of daily living”.tw.
5. daily life activity/
6. (“quality of wellbeing” or QWB or “QWB SA”).tw.
7. (“health* year* equivalent*” or HYE*).tw.
8. “health status”.tw.
9. health status/
10. health status indicators/
11. psychometric*.tw.
12. psychometry/
13. (“short form 36” or “SF-36” or SF36).tw.
14. (“short form 20” or “SF-20” or SF20).tw.
15. (“short form 12” or “SF-12” or SF12).tw.
16. (“short form 8” or “SF-8” or SF8).tw.
17. exp questionnaire/
18. or/20-36
19. 13 and 16 and 19 and 37
20. limit 38 to (english language and yr=”2004 -Current”)

Strategy

Lines 1–9: see Web of Science clinical effectiveness strategy.

1. Title=((“quality of life” or QoL or HRQL or HRQoL)) OR Topic=((“quality of life” or QoL or HRQL or HRQoL))
2. Title=((“quality adjusted life year*” or QALY*)) OR Topic=((“quality adjusted life year*” or QALY*))
3. Title=(“activities of daily living”) OR Topic=(“activities of daily living”)
4. Title=((“quality of wellbeing" or QWB or "QWB SA")) OR Topic=((“quality of wellbeing” or QWB or “QWB SA”))
5. Title=((“health* year* equivalent*” or HYE*)) OR Topic=((“health* year* equivalent*” or HYE*))
6. Title=(“health status”) OR Topic=(“health status”)
7. Title=(psychometric*) OR Topic=(psychometric*)
8. Title=((“short form 20” or “SF-20” or SF20)) OR Topic=((“short form 20” or “SF-20” or SF20))
9. Title=((“short form 12” or “SF-12” or SF12)) OR Topic=((“short form 12” or “SF-12” or SF12))
10. Title=((“short form 8” or “SF-8” or SF8)) OR Topic=((“short form 8” or “SF-8” or SF8))
11. Title=((Euroqol or “EQ-5D”)) OR Topic=((Euroqol or “EQ-5D”))
12. #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10
13. #21 AND #9 AND #8 AND #7 Timespan=2004-2013

Strategy

Lines 1–15: see CINAHL clinical effectiveness strategy.

1. TI(“quality of life” or QoL or HRQL or HRQoL) OR AB(“quality of life” or QoL or HRQL or HRQoL)
2. (MH “Quality of Life+”)
3. TI(“quality adjusted life year*” or QALY*) OR AB(“quality adjusted life year*” or QALY*)
4. (MH “Quality-Adjusted Life Years”)
5. TI(“activities of daily living”) OR AB(“activities of daily living”)
6. (MH “Activities of Daily Living+”)
7. TI(“quality of wellbeing” or QWB or “QWB SA”) OR AB(“quality of wellbeing” or QWB or “QWB SA”)
8. TI(“health* year* equivalent*” or HYE*) OR AB(“health* year* equivalent*” or HYE*)
9. TI(“health status”) OR AB(“health status”)
10. (MH “Health Status+”)
11. (MH “Health Status Indicators”)
12. TI(psychometric*) OR AB(psychometric*)
13. (MH “Psychometrics”)
14. TI(“short form 36” or “SF-36” or SF36) OR AB(“short form 36” or “SF-36” or SF36)
15. TI(“short form 20” or “SF-20” or SF20) OR AB(“short form 20” or “SF-20” or SF20)
16. TI(“short form 12” or “SF-12” or SF12) OR AB(“short form 12” or “SF-12” or SF12)
17. TI(“short form 8” or “SF-8” or SF8) OR AB(“short form 8” or “SF-8” or SF8)
18. TI(Euroqol or “EQ-5D”) OR AB(Euroqol or “EQ-5D”)
19. (MH “Questionnaires+”)
20. S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34
21. S9 AND S12 AND S15 AND S35

Date limited 2004-current.

Strategy

(TI,AB((erythropoietin* or EPO or erythropoiesis) OR (epoetin near/1 (alfa or beta or theta or zeta)) OR (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp))) AND (TI,AB(anaemi* or anemi*)) AND (TI,AB(cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or lymphoma* or oncolog* or chemotherap*))

Date limited 2004–current.

Strategy

See CENTRAL clinical effectiveness strategy.

Strategy

1. (erythropoietin* or EPO).tw.
2. erythropoiesis.tw.
3. (epoetin adj1 (alfa or beta or theta or zeta)).tw.
4. darbepoetin.tw.
5. CERA.tw.
6. (eprex or erypo or HEXAL or procrit or abseamed or epogen or binocrit or neorecormon or eporatio or retacrit or silapo or aranesp).tw.
7. or/1-6
8. an?emi?.tw.
9. (cancer* or carcinom* or leukemia or neoplasm* or malignan* or tumo?r* or myelo* or lymphoma* or oncolog* or chemotherap*).tw.
10. 7 and 8 and 9
11. limit 10 to yr=“2004 -Current”

MEDLINE(R)

Host: Ovid.

Data parameters: 1946 to September Week 1 2013.

Date searched: 17 September 2013.

Searcher: SB.

Hits: 159.

Strategy

1. (haemoglobin* or hemoglobin*).tw.
2. exp Hemoglobins/
3. (hgb or hb).tw.
4. or/1-3
5. ((post or after* or subsequent* or following) adj5 chemo*).tw.
6. postchemo*.tw.
7. or/5-6
8. an?emi?.tw.
9. exp anemia/
10. or/8-9
11. 4 and 7 and 10

MEDLINE(R)

Host: Ovid.

Data parameters: 1946 to September Week 1 2013.

Date searched: 18 September 2013.

Searcher: SB.

Hits: 258.

Strategy

1. (haemoglobin* or hemoglobin*).tw.
2. exp hemoglobins/
3. (hgb or hb).tw.
4. or/1-3
5. an?emi?.tw.
6. exp anemia/
7. or/5-6
8. (utility or utilities or “EQ-5D” or “SF-6D” or “EORTC-QLQ-C30” or HUI2 or “time trade-off” or TTO or “standard gamble” or SG or “quality-adjusted life year*” or QALY? or “discrete choice” or “stated preference”).tw.
9. Quality-Adjusted Life Years/
10. 8 or 9
11. 4 and 7 and 10